Remegen Co-h Stock price
AI Insights on Remegen Co-h
Insights
Is Remegen Co-h a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,102 stocks worldwide.
Key metrics
Remegen Co-h Stock Analysis
Analyst Opinions
13 Analysts have issued a Remegen Co-h forecast:
Analyst Opinions
13 Analysts have issued a Remegen Co-h forecast:
Remegen Co-h Events
Upcoming Event
Don't miss a Thing! We will send you all news about Remegen Co-h directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
RemeGen Co Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Yantai, Shandong and currently employs 2,999 full-time employees. The company went IPO on 2020-11-09. RemeGen Co Ltd is a China-based company principally engaged in biopharmaceutical research, biopharmaceutical service, biopharmaceutical production and sale. The firm focuses on therapeutic antibody drugs such as antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company’s main products include telitacicept, disitamab vedotin, RC28-E and others. The firm's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The firm mainly operates its businesses in the domestic and overseas markets.
| Head office | China |
| CEO | Mr. Fang |
| Employees | 3,048 |
| Website | www.remegen.cn |


